Cutaneous melanoma by Négrier, S et al.
Cutaneous melanoma is a highly malignant tumour. The incidence
has increased dramatically over the last few decades and is now
estimated at between 4–5000 new cases per year in France. 
The term ‘naevus’, unless otherwise specified, refers to an
acquired or congenital benign melanocytic tumour (commonly
known as a naevus, naevi or mole). A melanoma can develop de
novo, or within a pre-existing benign naevus. A melanoma can
arise in any area containing melanocytes, but approximately 90%
are cutaneous tumours. 
These recommendations refer to localized primary tumours,
those presenting with regional nodes and those with distant
metastases. The management of mucosal, visceral and ophthalmic
melanomas is not covered. 
These recommendations are based on literature published until
the end of 1998. Data published since does not change these
recommendations. An update is planned for early 2001. 
RISK FACTORS AND PREVENTION 
The identification of risk factors is useful for the prevention of
melanoma. Two types of risk factors have been identified: indi-
vidual (constitutional) factors (photosensitivity, numerous naevi,
atypical naevi, giant congenital naevi, personal or family history
of melanoma) and behavioural factors (excess exposure to sun or
artificial ultraviolet rays) (level of evidence A). 
The primary prevention of melanoma depends on a reduction in
exposure to ultraviolet rays, either solar or artificial. Secondary
prevention is based on the early diagnosis of a melanoma at a
curable stage and the surveillance of high-risk patients. 
DIAGNOSIS AND HISTOPATHOLOGICAL
ASSESSMENT 
Diagnosis is the first step in the management of a melanoma (stan-
dard). Certain clinical criteria in a pigmented cutaneous lesion are
suggestive of malignancy (standard). The criteria are classified as
follows: 
l criteria A : asymmetry 
l criteria B : irregular borders 
l criteria C : heterogeneous colour 
l criteria D : large diameter 
l criteria E : evolution (recent change) – this criteria must co-
exist with at least one of the preceding criteria. 
Some authors use the three change criteria: change in size, colour
and shape. Other authors have proposed a list of seven criteria:
three major criteria (change in size, change in colour, change in
shape) and four minor criteria (diameter greater than 7 mm, hyper-
sensitivity, bleeding and inflammation). 
Epiluminescence microscopy (ELM), or dermatoscopy, can
improve the clinical diagnosis of pigmented lesions. It can differ-
entiate a melanocytic from a non-melanocytic pigmented lesion
such as a seborrheic keratosis, pigmented basal-cell carcinoma or
haemangioma. Dermatoscopy for the early diagnosis of a mela-
noma should only be used by those familiar with the technique.
Its accuracy depends on the experience of the dermatologist.
Currently, it cannot be recommended as a routine technique. 
The standard practice for the management of cutaneous melano-
cytic lesions thought to be malignant is a limited but complete
excision under local anaesthetic of the lesion with a narrow rim
(2 mm) of normal skin. The incision will usually be elliptical with
the long axis parallel to the skin lines to allow for re-excision with
minimal skin loss. If the initial excision is incorrect (for example a
transverse incision across a forearm rather than a longitudinal
incision down the arm) a skin graft may be necessary at the time of
re-excision. 
Cutaneous lesions should be excised rather than biopsied for the
following reasons: 
l if the lesion is benign, there is no need for further treatment 
l there is a risk of misdiagnosis if a melanocytic lesion is only
partially examined 
l an examination of the entire lesion is necessary to assess all
histological parameters, maximum thickness in particular. 
The thickness of the lesion and the clearance of the margins can
only be determined by histological examination. Tissue destruc-
tion can compromise the final diagnosis and the assessment of
histological prognostic factors. A scalpel rather than a laser or
electro-coagulation should therefore be used for the excision. All
excisional or incisional biopsies must be sent to the pathologist
(standard). Frozen sections must be discouraged. Excision margins
should be documented in the operation note. Standard histological
examination is generally sufficient. 
The amount of information that can be obtained from the
excised sample depends on the quality of the specimen. The age,
the sex of the patient and the site of the lesion are mandatory for
the histopathological interpretation. Immunohistochemistry alone
cannot provide a diagnosis of malignancy and should not be used
routinely. It can, however, confirm the melanocytic nature of a
cutaneous lesion with an unusual presentation, whether it is
primary or secondary (particularly for non-pigmented lesions) and
can improve the detection of occult metastases in lymph nodes. 
The histopathological report must include at least (NIH
consensus conference of 1992 and the French Consensus
Conference of 1995) the: 
l diagnosis of the melanocytic nature of the lesion and
confirmation of its malignancy 
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Breslow’s method). 
l assessment of completeness of excision of invasive and in situ
components; microscopic measurement of the shortest extent
of clearance 
l level of invasion (Clark) 
l presence and extent of regression 
l presence and extent of ulceration. 
Optional parameters are: 
l histological type and special variants 
l pre-existing lesion 
l mitotic rate 
l vascular invasion 
l neurotropism 
l cell type 
l tumour lymphocyte infiltration 
l growth phase; vertical or radial. 
A complete clinical examination is standard for an isolated
primary melanoma to detect a second primary melanoma and/or
metastases, including nodal metastases. The clinical examination
must include an examination of the entire skin surface (including
scalp) and of all regional nodes (standard). In the case of an
isolated primary melanoma with no clinically detectable nodes,
there is no need for further investigations. Studies have shown that
the risk of nodal involvement is correlated with the maximum
thickness and level of invasion of the primary tumour. There is no
indication for routine nodal dissection for diagnosis or staging;
this has no impact on survival and the surgery carries significant
morbidity. There is no effective adjuvant treatment. An ultrasound
of superficial regional nodes is indicated for cases of clinical
uncertainty (option). 
Sentinel nodes can be identified by blue dye or a radio-labelled
colloid marker. This is not a routine procedure, since no gain in
survival has been demonstrated after nodal dissection and/or with
adjuvant treatment in the case of tumour involvement of a sentinel
node. Nodes can be identified electively with a morbidity of
almost zero. These techniques facilitate planned lymph-node
dissection to detect microscopic metastases. 
Technetium lymphoscintigraphy can localize nodal drainage
pathways for melanomas situated in medial regions (head, neck,
trunk). This is only of interest if prophylactic nodal dissection is
planned within a prospective study (e.g. the sentinel node study
according to Morton’s technique). 
In cases of regional or metastatic nodal involvement, a search
for other metastatic lesions is justified to guide subsequent
therapy. In about 10% of cases distant asymptomatic metastases
are discovered at the time of diagnosis of involved nodes. There is
no consensus regarding the efficacy of imaging techniques to
detect distant metastases; abdominal, thoracic and cerebral CT
scans seem the most useful. Other investigations can be made
according to physical signs. Immunoscintigraphy is still in the
process of development and is not recommended in routine prac-
tice to demonstrate clinically undetectable metastases. 
For patients with metastatic disease at any site at presentation, a
search for the primary tumour must include a careful history of
any previous treatment to a cutaneous lesion and an examination
of the whole body (standard). In the case of an isolated node, cyto-
logical analysis of a sample obtained by fine-needle aspiratation
can be considered as a diagnostic, aid but a definitive diagnosis
can only be made following histopathological examination of
tissue (standard). If a pigmented lesion is found to contain melanin
by histochemistry, there is no need for immunohistochemistry. If
the lesion is achromic, immunohistochemistry is necessary to
confirm melanocytic origin. 
Histopathological examination of lymph nodes requires at least
one section through the centre of each node (standard). The
number of nodes examined, the number of involved nodes and any
capsular rupture must be reported (standard). If there is nodal
involvement, the number of nodes greater than 3 cm should be
defined by TNM classification criteria. If there is no evidence of
nodal invasion on microscopy, immunohistochemistry should be
used for the detection of occult metastases. 
Polymerase chain reaction (PCR) is not a validated technique in
melanoma and should not be used routinely. 
CLASSIFICATION AND PROGNOSTIC FACTORS 
Five different international classifications are accepted to define
the clinical stages of melanoma. The AJCC/UICC classification 
(option) is used most often in English-speaking countries and in
the literature. 
For single excisable melanomas, the Breslow index is the most
powerful and most commonly used prognostic factor (level of
evidence A). There is a close correlation between survival and the
Breslow index. For thin melanomas (Breslow index less than 1
mm), the level of invasion (Clark’s level) has prognostic value.
Other clinical criteria (sex, age, site of the lesion) have prognostic
value (level of evidence C), but these parameters have complex
inter-relations and their value is low when compared to that of the
Breslow index. 
When a melanoma presents with locoregional node involve-
ment, the number of involved nodes is the most important prog-
nostic factor (level of evidence B). For patients with metastatic
melanoma, the number of metastatic sites and the time interval
between the primary tumour and the metastases appear/to be the
most important prognostic factors. 
TREATMENT MODALITIES 
Surgery 
The standard treatment of a localized primary melanoma is surgery
(Figure 1). After initial surgery, a wider second excision may be
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PRIMARY LOCALIZED CUTANEOUS
MELANOMA
Standards
· surgery: repeat surgery with margins according to the tumour
· no nodal clearance
· no adjuvant treatment
Follow-up
Figure 1 Treatment of primary localized cutaneous melanomanecessary with margins depending on the results of the initial histo-
logical examination (standard). These margins will vary according
to the depth of the tumour, specifically the Breslow index (stan-
dard). In France there are two guidelines which are used to base the
extent of excision margins; those established by ANDEM in 1994
and those of the French consensus conference in 1995. The
ANDEM system is recommended on the basis of simplicity and
compatability with published data (level of evidence B). 
The required margin of excision is dependent on the thickness
of the lesion: 
l melanoma in situ (non invasive): margin of 0.5 cm from edge
to edge 
l Breslow melanoma ≤ 1 mm: margin of 1 cm 
l melanoma with Breslow ³ 1 mm, ≤ 2 mm: margins of 1–2 cm 
l melanoma with Breslow ³ 2 mm, ≤ 4 mm: margins of 2 cm 
l melanoma with Breslow > 4 mm: margins of 3 cm. 
For melanomas of Breslow thickness less than 1 mm, the same
recommendations were made at the time of the NIH consensus
conference in 1992. There is no consensus dealing with the exci-
sion margins in cases where tumour regression is noted on histo-
logical examination. The excision margins should be those for
lesions in the category immediately above the actual thickness. 
The value of regional nodal dissection is controversial and the
data in the literature are contradictory. The theoretical aims of
prophylactic nodal dissection are to improve overal survival (by
diminishing the risk of metastases by spread from involved nodes)
and to provide prognostic information (although this will not be
useful until there is effective adjuvant treatment). Nodal dissection
should only be considered for lesions on the limbs where there is a
single route of lymph drainage. Surgery is always associated with
some morbidity, especially in the lower limbs. The early complica-
tion rate is between 10–15% in the best series of inguinal dissec-
tion. The rate of late lymphoedema is between 6–15% in the lower
limbs and 6% in the upper limbs. At the present time, routine nodal
dissection after excision of an isolated cutaneous melanoma is not
recommended (level of evidence C). 
Radiotherapy 
There is no indication for radiotherapy in operable melanoma
excised with adequate margins (standard) (Figure 1). 
Adjuvant therapy 
There is no survival advantage when adjuvant chemotherapy is
given after excision of an isolated tumour or after excision of
nodal metastases (level of evidence B). Adjuvant chemotherapy
should not be given outside a trial. No survival advantage has been
shown from the use of hormone therapy (progestogens) in the
adjuvant setting (level of evidence B). Adjuvant hormone therapy
should not be used outside a study. The results of controlled
studies of immunotherapy in the adjuvant setting have not been
consistent, but suggest that a benefit may be possible for certain
sub-groups of patients (level of evidence C). Adjuvant intra-arte-
rial infusions have not been shown to be of definite benefit (level
of evidence B). Intra-arterial perfusion therapy with hyperthermia
and/or chemotherapy and/or immunotherapy should not be consid-
ered as primary therapy and must only be undertaken by experi-
enced teams within controlled studies. 
THERAPEUTIC STRATEGY 
Treatment of localized primary melanoma 
The standard treatment of a localized primary melanoma is surgery
(Figure 1). After initial surgery, a wider second excision may be
necessary with margins depending on the results of the initial
histological examination (standard). These margins will vary
according to the depth of the tumour, specifically the Breslow
index (standard). There is no indication for radiotherapy (standard)
or adjuvant chemotherapy (level of incidence B, standard). 
Treatment of regional node involvement 
The standard treatment of patients presenting with regional node
involvement, whether it be the presenting feature, a synchronous
presentation with the primary tumour, or the first indication of
recurrence, is surgical dissection of involved nodes (Figure 2). No
other treatment has been shown to be superior (level of evidence
B). The appropriate surgery is nodal dissection, although there is
no consensus regarding its extent. After complete nodal dissection,
there is no indication for any further treatment (level of evidence
B). Adjuvant radiotherapy has not been shown to be of benefit
after complete nodal clearance (level of evidence C). Radiotherapy
is an option in the case of incomplete nodal clearance, for example
in the case of fixed nodes, extensive invasion or capsular disrup-
tion. 
Controlled studies of adjuvant immunotherapy have given
inconsistent results but suggest that there may be a benefit in sub-
groups of patients, in particular those patients with metastatic
regional nodes (level of evidence C). Adjuvant therapy with inter-
feron has shown a significant advantage in terms of overall
survival in one study (level of evidence C), which was not
confirmed by a subsequent study. This therapy has considerable
toxicity and patients must be strictly selected and closely followed
during treatment. Adjuvant immunotherapy is an option for operable
patients with regional nodal metastases, but cannot be recommended
Cutaneous melanoma 83
British Journal of Cancer (2001) 84 (Supplement 2), 1–5 © 2001 FNCLCC
CUTANEOUS MELANOMA WITH
REGIONAL NODE INVOLVEMENT
Satisfactory excision with
adequate  margins and  complete
nodal clearance?
Standards
· surgery or repeat surgery with excision margins
   according to the thickness of the tumour
· nodal clearance
Standard
no additional treatment
Option
adjuvant therapy with interferon alpha
Standards
· repeat surgery, if surgical margins
   are unsatisfactory
· nodal clearance if not done
Follow-up
yes no
Figure 2 Treatment of cutaneous melanoma with regional node involvementas primary/first-line treatment in operable melanoma with or
without involved nodes. Further randomized controlled studies are
required to confirm the potential role of adjuvant immunotherapy. 
Treatment of an isolated local recurrence 
Surgical excision is the standard treatment. 
Treatment of metastatic melanoma 
There is no standard therapy for metastatic melanoma (Figure 3).
With the possible exception of the resection of in-transit metas-
tases or slowly developing single metastases, there is no curative
treatment. Therapy should be adapted according to the number of
lesions, the rate of progression of the disease and the performance
status of the patient. Some palliative chemotherapy and immuno-
therapy protocols have resulted in significant tumour regression
with a median duration of remission of 4 to 5 months. Conventional
palliative chemotherapy is dacarbazine. Polychemotherapy has not
been shown to be superior to dacarbazine alone with respect to
survival (level of evidence B). The exact role of immunotherapy in
the treatment of metastatic disease remains to be determined. 
Treatment of a Hutchinson’s melanotic freckle or
lentigo maligna (melanoma in situ) 
The standard treatment is surgical excision with a margin of
0.5 cm (see Figure 4). 
Treatment of in-transit metastases 
The standard treatment for in-transit metastases (more than 3–5
cm from the primary lesion) is surgical excision (Figure 5). In the
case of very numerous metastases, treatment by perfusion of an
isolated limb can be considered (level of evidence C). This should
only be done by a specialized team trained in this technique. 
FOLLOW-UP 
Follow-up is based on clinical examination (standard). Self-
surveillance should be encouraged by the provision of relevant
patient information (standard). Surveillance is indicated in all
cases throughout life (standard), especially in the case of an
isolated operable melanoma. There is no case for routine blood
tests or imaging in the absence of clinical signs or symptoms.
There is no international consensus as to the pattern of follow-up.
In France, the recommendations for follow-up are as follows. 
Melanoma in situ 
After complete excision with adequate excision margins, the risk
of local recurrence is negligible. Patients should be followed
annually throughout life in order to detect a second melanoma. 
Melanoma with a Breslow index of less than 1.5 mm
Follow-up every 6 months for 10 years, then annually throughout
life. 
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Standard
there is no standard
Options
· limited surgery
· radiotherapy
· palliative chemotherapy
Follow-up
METASTATIC MELANOMA
Figure 3 Treatment of metastatic melonoma
HUTCHINSON'S  MELANOTIC FRECKLE OR LENTIGO MALIGNA
Standard
surgery with a margin of 0.5 cm
Option
if complete exicision is impossible or contra-indicated:
·  radiotherapy
·  CO2 laser
·  cryotherapy
Follow-up
Figure 4 Treatment of Hutchinsons melanotic freckle
MELANOMA WITH IN-TRANSIT METASTASES
Standard
surgery with complete excision of all lesions
Option
intra-arterial chemotherapy to isolated limb ± hyperthermia
Follow-up
Figure 5 Treatment of melanoma with in-transit metastasesMelanoma with a Breslow index of greater than 1.5 mm
or with histological regression whatever the depth, or
with a level of Clark equal to IV or V
Follow-up every 3 months for 4 years, every 6 months for years
5–10, then annually throughout life. The rate of recurrence beyond
the fifth year is the same whatever the Breslow index of the initial
tumour. 
Advanced disease 
There is no consensus regarding the approach to follow-up. 
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